Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool
Loading...
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity and that can predict therapeutic response. Fortunately, the emergence of patient-derived organoid (PDOs) culture has enabled the ex vivo mimicking of the pathophysiology of human tumors with the reassembly of tissue-specific features. These features include histopathological variability, molecular expression profiles, genetic and cellular heterogeneity of parental tissue, and furthermore growing evidence suggests the ability to predict patient therapeutic response. Concentrating on the highly lethal and heterogeneous gastrointestinal (GI) tumors, herein we present the state-of-the-art and the current methodology of PDOs. We highlight the potential additions, improvements and testing required to allow the ex vivo of study the tumor microenvironment, as well as offering commentary on the predictive value of clinical response to treatments such as chemotherapy and immunotherapy.
Description
Keywords
Patient‑derived organoid, Gastrointestinal cancer, Pre‑clinical model, Drug response prediction, Immunotherapy, Tumor microenvironment
Citation
Biological Research. 2023 Dec 02;56(1):63